IL269134B2 - Antibodies against PAR2 and their use - Google Patents

Antibodies against PAR2 and their use

Info

Publication number
IL269134B2
IL269134B2 IL269134A IL26913419A IL269134B2 IL 269134 B2 IL269134 B2 IL 269134B2 IL 269134 A IL269134 A IL 269134A IL 26913419 A IL26913419 A IL 26913419A IL 269134 B2 IL269134 B2 IL 269134B2
Authority
IL
Israel
Prior art keywords
antibody
antigen
binding fragment
seq
amino acid
Prior art date
Application number
IL269134A
Other languages
English (en)
Hebrew (he)
Other versions
IL269134B1 (en
IL269134A (en
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of IL269134A publication Critical patent/IL269134A/en
Publication of IL269134B1 publication Critical patent/IL269134B1/en
Publication of IL269134B2 publication Critical patent/IL269134B2/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pain & Pain Management (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
IL269134A 2017-03-16 2018-03-16 Antibodies against PAR2 and their use IL269134B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762472462P 2017-03-16 2017-03-16
US201862637766P 2018-03-02 2018-03-02
PCT/EP2018/056776 WO2018167322A1 (en) 2017-03-16 2018-03-16 Anti-par2 antibodies and uses thereof

Publications (3)

Publication Number Publication Date
IL269134A IL269134A (en) 2019-11-28
IL269134B1 IL269134B1 (en) 2024-03-01
IL269134B2 true IL269134B2 (en) 2024-07-01

Family

ID=61827709

Family Applications (1)

Application Number Title Priority Date Filing Date
IL269134A IL269134B2 (en) 2017-03-16 2018-03-16 Antibodies against PAR2 and their use

Country Status (22)

Country Link
US (3) US10836822B2 (enExample)
EP (1) EP3596125B1 (enExample)
JP (3) JP7222901B2 (enExample)
KR (1) KR102711884B1 (enExample)
CN (1) CN110446720B (enExample)
AU (3) AU2018235031B2 (enExample)
BR (1) BR112019018752A2 (enExample)
CA (1) CA3055251A1 (enExample)
CL (1) CL2019002626A1 (enExample)
CO (1) CO2019010975A2 (enExample)
CR (1) CR20190417A (enExample)
IL (1) IL269134B2 (enExample)
MA (1) MA49886A (enExample)
MX (1) MX2019010802A (enExample)
NZ (1) NZ757915A (enExample)
PH (1) PH12019502087A1 (enExample)
PT (1) PT3596125T (enExample)
SG (1) SG11201908056QA (enExample)
TW (1) TWI788332B (enExample)
UA (1) UA125757C2 (enExample)
WO (1) WO2018167322A1 (enExample)
ZA (1) ZA201906004B (enExample)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NZ717429A (en) 2008-04-11 2018-07-27 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CN108715614A (zh) 2010-11-30 2018-10-30 中外制药株式会社 与多分子的抗原重复结合的抗原结合分子
CN112812184A (zh) 2011-02-25 2021-05-18 中外制药株式会社 FcγRIIb特异性Fc抗体
US20150050269A1 (en) 2011-09-30 2015-02-19 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule promoting disappearance of antigens having plurality of biological activities
TWI617580B (zh) 2014-12-19 2018-03-11 中外製藥股份有限公司 抗ｃ５抗體及使用方法
KR102650420B1 (ko) 2014-12-19 2024-03-21 추가이 세이야쿠 가부시키가이샤 항-마이오스타틴 항체, 변이체 Fc 영역을 함유하는 폴리펩타이드, 및 사용 방법
KR102605798B1 (ko) 2015-02-05 2023-11-23 추가이 세이야쿠 가부시키가이샤 이온 농도 의존적 항원 결합 도메인을 포함하는 항체, Fc 영역 개변체, IL-8에 결합하는 항체, 및 그들의 사용
JP7141336B2 (ja) 2015-12-25 2022-09-22 中外製薬株式会社 抗ミオスタチン抗体および使用方法
TW202300168A (zh) 2016-08-05 2023-01-01 日商中外製藥股份有限公司 Il-8相關疾病之治療用或預防用組成物
JP7191833B2 (ja) 2017-01-30 2022-12-19 中外製薬株式会社 抗スクレロスチン抗体およびその使用
CN110446720B (zh) * 2017-03-16 2023-09-12 免疫医疗有限公司 抗par2抗体及其用途
US12214216B1 (en) 2019-10-16 2025-02-04 Helen Feng Photon enhanced bone growth system and method
US11725052B2 (en) 2020-08-18 2023-08-15 Cephalon Llc Anti-PAR-2 antibodies and methods of use thereof
GB202204159D0 (en) 2022-03-24 2022-05-11 Heptares Therapeutics Ltd Antibodies
AU2024212070A1 (en) 2023-01-25 2025-07-31 Medimmune Limited Migraine therapy
WO2025172573A1 (en) 2024-02-16 2025-08-21 Domain Therapeutics Combinations of par2 inhibitors and immune checkpoint inhibitors for the treatment of cancer
WO2025191185A1 (en) 2024-03-15 2025-09-18 Domain Therapeutics Azine-based compounds as par-2 inhibitors and therapeutic uses thereof

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031695A1 (en) * 2009-09-09 2011-03-17 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human protease-activated receptor-2
WO2011111007A2 (en) * 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
WO2014028354A1 (en) * 2012-08-13 2014-02-20 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
WO2016000813A1 (en) * 2014-06-30 2016-01-07 Merck Patent Gmbh Anti-tnfa antibodies with ph-dependent antigen binding

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK1355919T3 (da) 2000-12-12 2011-03-14 Medimmune Llc Molekyler med længere halveringstider, sammensætninger og anvendelser deraf
EP1604207A2 (en) * 2003-03-11 2005-12-14 Bayer HealthCare AG Diagnostics and therapeutics for diseases associated with g-protein coupled proteinase activated receptor 2 (par2)
JP5848861B2 (ja) 2004-04-20 2016-01-27 ジェンマブ エー／エスＧｅｎｍａｂ Ａ／Ｓ Ｃｄ２０に対するヒトモノクローナル抗体
JP2008519039A (ja) * 2004-11-04 2008-06-05 ニュー イングランド メデカル センター ホスピタルズ インク Ｇタンパク質共役型受容体アゴニストおよびアンタゴニストならびに使用方法
US20100034194A1 (en) 2006-10-11 2010-02-11 Siemens Communications Inc. Eliminating unreachable subscribers in voice-over-ip networks
CL2008001887A1 (es) 2007-06-29 2008-10-03 Amgen Inc Proteinas de union a antigeno que se unen al receptor activado por proteasas 2 (par-2); acido nucleico que las codifica; vector y celula huesped; metodo de produccion; y composicion que las comprende.
AR070911A1 (es) 2008-03-19 2010-05-12 Regeneron Pharma Uso de antagonistas del receptor par2 activado con proteasa
NZ717429A (en) 2008-04-11 2018-07-27 Chugai Pharmaceutical Co Ltd Antigen-binding molecule capable of binding to two or more antigen molecules repeatedly
CA2722600C (en) 2008-05-01 2014-01-21 Amgen Inc. Anti-hepcidin antibodies and methods of use
JP2011530515A (ja) 2008-08-05 2011-12-22 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング Ｐａｒ−２活性化のエフェクターおよび炎症の調節におけるその使用
US20150203591A1 (en) 2012-08-02 2015-07-23 Regeneron Pharmaceuticals, Inc. Mutivalent antigen-binding proteins
CN110446720B (zh) * 2017-03-16 2023-09-12 免疫医疗有限公司 抗par2抗体及其用途

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011031695A1 (en) * 2009-09-09 2011-03-17 Regeneron Pharmaceuticals, Inc. High affinity human antibodies to human protease-activated receptor-2
WO2011111007A2 (en) * 2010-03-11 2011-09-15 Rinat Neuroscience Corporation ANTIBODIES WITH pH DEPENDENT ANTIGEN BINDING
WO2014028354A1 (en) * 2012-08-13 2014-02-20 Regeneron Pharmaceuticals, Inc. Anti-pcsk9 antibodies with ph-dependent binding characteristics
WO2016000813A1 (en) * 2014-06-30 2016-01-07 Merck Patent Gmbh Anti-tnfa antibodies with ph-dependent antigen binding

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
IGAWA T ET AL:, PH-DEPENDENT ANTIGEN-BINDING ANTIBODIES AS A NOVEL THERAPEUTIC MODALITY, 12 August 2014 (2014-08-12) *
PAULINE BONVIN ET AL:, PURPOSE-ORIENTED ANTIBODY LIBRARIES INCORPORATING TAILORED CDR3 SEQUENCES, 20 May 2015 (2015-05-20) *
T IGAWA:, ANTIBODY RECYCLING BY ENGINEERED PH-DEPENDENT ANTIGEN BINDING IMPROVES THE DURATION OF ANTIGEN NEUTRALIZATION., 28 November 2011 (2011-11-28) *

Also Published As

Publication number Publication date
CL2019002626A1 (es) 2019-12-06
CA3055251A1 (en) 2018-09-20
UA125757C2 (uk) 2022-06-01
PH12019502087A1 (en) 2020-03-09
JP2020509762A (ja) 2020-04-02
KR20190129925A (ko) 2019-11-20
JP2023055895A (ja) 2023-04-18
AU2021257983B2 (en) 2025-02-27
TWI788332B (zh) 2023-01-01
US20210061905A1 (en) 2021-03-04
AU2018235031A1 (en) 2019-10-31
EP3596125B1 (en) 2025-11-19
CN110446720A (zh) 2019-11-12
AU2021257983A1 (en) 2021-11-25
TW201843176A (zh) 2018-12-16
JP7222901B2 (ja) 2023-02-15
US10836822B2 (en) 2020-11-17
CR20190417A (es) 2019-12-06
EP3596125A1 (en) 2020-01-22
KR102711884B1 (ko) 2024-10-02
NZ757915A (en) 2023-05-26
IL269134B1 (en) 2024-03-01
MA49886A (fr) 2020-06-24
BR112019018752A2 (pt) 2020-05-05
AU2025203947A1 (en) 2025-06-19
AU2018235031B2 (en) 2021-08-12
CN110446720B (zh) 2023-09-12
MX2019010802A (es) 2019-10-30
CO2019010975A2 (es) 2019-10-21
SG11201908056QA (en) 2019-09-27
US11591389B2 (en) 2023-02-28
ZA201906004B (en) 2025-10-29
PT3596125T (pt) 2025-11-27
US20230242639A1 (en) 2023-08-03
JP2025102812A (ja) 2025-07-08
WO2018167322A1 (en) 2018-09-20
IL269134A (en) 2019-11-28
US20180305450A1 (en) 2018-10-25

Similar Documents

Publication Publication Date Title
AU2021257983B2 (en) Anti-par2 antibodies and uses thereof
US9260515B2 (en) Antibodies to human GDF8
TW202019966A (zh) 雙特異性抗－ＢＣＭＡｘ抗－ＣＤ３抗體及其用途
ES3040144T3 (en) Antigen-binding proteins that antagonize leptin receptor
US20240309100A1 (en) Anti-Trkb Monoclonal Antibodies And Methods Of Use
CA3094286A1 (en) Gipr antibody and its fusion protein with glp-1, and pharmaceutical composition and application thereof
US12110336B2 (en) Method for treating a neurodegenerative disease by administering an anti-cellular prion protein (PrPc) antibody
EA044850B1 (ru) Антитела к par2 и пути их применения
TW202519547A (zh) 雙特異性PD-L1x4-1BB抗體及其使用方法
TW202519559A (zh) 雙特異性PD-L1xCD28抗體及其使用方法
HK1183042A (en) Antibodies to human gdf8